Aravive Investor Presentation Deck
Effective Treatment of Human Tumors Requires Drugs that
Target Non-metastatic and Metastatic Tumor Cells
#
Batiraxcept demonstrates single agent activity in preclinical models which have
homogeneous, metastatic tumor cells
Human tumors display epithelial-mesenchymal heterogeneity 1,2,3
Cells within the same tumor can exhibit different phenotypes: epithelial (E);
mesenchymal (M); or one or more hybrid epithelial-mesenchymal phenotypes.
Phenotypic heterogeneity is a hallmark of aggressive cancer behavior and a clinical
challenge
Chemotherapies, targeted therapies and IO therapies have all been reported to
increase the GAS6/AXL signaling
> Effective treatment requires drug(s) to affect both E and M populations
Batiraxcept does not target rapidly dividing epithelial cells nonspecifically like
chemotherapeutics but targets mesenchymal, invasive cells
Need agent to inhibit/decrease epithelial cell growth as well as inhibit/prevent
mesenchymal cell growth
1 PLOS Computational Biology | https://doi.org/10.1371/journal pcbi.1007619 February 10, 2020
2 Safa, J Cancer Metastasis Treat 2020;6:36
3 Biomolecules 2022, 12, 348, https://doi.org/10.3390/biom12030348
ZEB mRNA molecules
1200
1000
8:00
600
400
200
0
100
E
E/M
150
200
SNAIL molecules (10)
250
M
Different stable (blue curves) ZEB
mRNA levels based on SNAIL levels
Low, medium, and high ZEB mRNA
levels corresponds to Epithelial (E).
Hybrid (E/M), and Mesenchymal (M)
phenotypes respectively. This bifurcation
diagram is for the miR-200/ZEB
feedback loop driven by SNAIL, as
adapted from Lu et al. PNAS 2013. From
ref #3
6
300View entire presentation